Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.44 |
| ▸ | TNKS | O95271 | 4/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PLD2 | O14939 | 1/20 | 0.40 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438837 | 0.80 | AVPR1A (0.48) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL10198071 | 0.80 | AVPR1A (0.46) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL13489657 | 0.79 | AVPR1A (0.46) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL13996311 | 0.77 | AVPR1A (0.48) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL13996306 | 0.76 | AVPR1A (0.46) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL1051338 | 0.71 | HSD11B1 (0.49) | AVPR1ACHRM1HSD11B1PLD2PLD1 | |
| SCHEMBL13490140 | 0.71 | ALDH1A1 (0.41) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL3390173 | 0.69 | AVPR1A (0.54) | AVPR1ACHRM1HSD11B1OPRM1 | |
| SCHEMBL14001194 | 0.68 | PLD2 (0.40) | AVPR1ACHRM1HSD11B1TNKSPARP2 | |
| SCHEMBL436837 | 0.68 | DRD4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | AVPR1A 3879/4885CHRM1 3056/4885HSD11B1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.